QIAGEN reports preliminary Q3 2019 results and announces measures to prioritize resource allocation
(WorldNews Netherlands)

Preliminary Q3 2019 sales of about 3% CER growth (vs.~4-5% CER outlook), adjusted EPS in line with outlook Initiatives announced to free up resources to invest in best growth opportunities, in particular new partnership with Illumina in NGS clinical decision-making Venlo, The Netherlands, October 07, 2019 -QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced preliminary sales results for the third quarter of 2019 and measures to prioritize resource allocation to the most attractive growth opportunities in its Sample to Insight portfolio, in particular in light of a new orientation for its next-generation sequencing (NGS) activities. For the third quarter of 2019, QIAGEN...